Syntopix agrees exclusive deal with world leader

Under the terms of the agreement, the Bradford-based company has granted the rights of first refusal to the company to enter talk for further development and eventual commercialisation of a compound that is currently under clinical evaluation.

Syntopix, which is a Leeds University spin-out, will receive payments throughout the clinical phase.

The Aim-listed business said the agreement builds on its key strategy of identifying potential compounds via its comprehensive antimicrobial and drug delivery screening technologies, and forming partnerships with leading healthcare and cosmetic companies to develop those products through to market.

Stephen Jones, chief executive, said: "I am delighted that we have signed this agreement with a global leader in personal care. Hygiene and personal care has become increasingly important to consumers and the market opportunity for effective antimicrobials is growing. We continue to look forward to working together with our partners to see Syntopix's compounds in well known consumer brands."